Labor epidural analgesia and subsequent risk of offspring autism spectrum disorder and attention-deficit/hyperactivity disorder: A cross-national cohort study of 4.5 million individuals and their siblings

Tor-Arne Hegvik, MD, PhD, Kari Klungsøyr, MD, PhD, Ralf Kuja-halkola, PhD, Hanna Remes, PhD, Jan Haavik, MD, PhD, Brian M. D’onofrio, PhD, Niina Metsä-simola, PhD, Anders Engeland, PhD, Seena Fazel, MD, Paul Lichtenstein, PhD, Pekka Martikainen, PhD, Henrik Larsson, PhD, Amir Sariaslan, PhD

PII: S0002-9378(22)00650-0
DOI: https://doi.org/10.1016/j.ajog.2022.08.016
Reference: YMOB 14680


Received Date: 4 May 2022
Revised Date: 31 July 2022
Accepted Date: 1 August 2022


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Author(s). Published by Elsevier Inc.
Labor epidural analgesia and subsequent risk of offspring autism spectrum disorder and attention-deficit/hyperactivity disorder: A cross-national cohort study of 4.5 million individuals and their siblings

Tor-Arne HEGVIK, MD, PhD; Kari KLUNGSØYR, MD, PhD; Ralf KUJA-HALKOLA, PhD; Hanna REMES, PhD; Jan HAAVIK, MD, PhD; Brian M. D’ONOFRIO, PhD; Niina METSÄ-SIMOLA, PhD; Anders ENGELAND, PhD; Seena FAZEL, MD; Paul LICHTENSTEIN, PhD; Pekka MARTIKAINEN, PhD; Henrik LARSSON, PhD; Amir SARIASLAN, PhD

1 Department of Biomedicine, University of Bergen, Bergen, Norway
2 Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
3 Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
4 Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Norway
5 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
6 Population Research Unit, Faculty of Social Sciences, University of Helsinki, Helsinki, Finland
7 Bergen Center for Brain Plasticity, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
8 Department of Psychological and Brain Sciences, Indiana University, Bloomington, United States
9 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom
10 Centre for Health Equity Studies (CHESS), Stockholm University and Karolinska Institutet, Stockholm, Sweden
11 Max Planck Institute for Demographic Research, Rostock, Germany
12 School of Medical Sciences, Örebro University, Örebro, Sweden

All correspondence should be sent to: Dr Amir Sariaslan, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom. E-mail: amir.sariaslan@psych.ox.ac.uk.

Acknowledgements
The study was supported by the Academy of Finland (#308247, #294861), University of Bergen, NevSom – Oslo University Hospital, the Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) framework (#340-2013-5867), the Swedish Research Council (#2014-3831), and the National Institute on Drug Abuse (R01DA048042). AS and SF are supported by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005). SF is further funded by the Wellcome Trust as part of a Senior Research Fellowship in Clinical Science.
PM has received funding from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101019329), and the NordForsk grant for the project WELLIFE (#83540). JH has been a speaker for Medice, Shire/Takeda and Biocodex. HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. The remaining authors declare that they have no conflicts of interest. The funders were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The study was approved by the Ethics Board of Statistics Finland (TK-53-1121-18), the Regional Committees for Medical Research Ethics in Norway (2020/75421) and the Regional Ethical Review Board in Stockholm, Sweden (2013/862-31/5).

**Author contributions**

Dr Sariaslan and Dr Hegvik had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Sariaslan, Hegvik

Acquisition, analysis, or interpretation of data: Sariaslan, Hegvik, Haavik, Engeland, Klungsøy, Larsson, Lichtenstein, Martikainen, Kuja-Halkola

Drafting of the manuscript: Sariaslan, Hegvik

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Sariaslan, Hegvik

Obtained funding: Haavik, Klungsøy, Larsson, Lichtenstein, Martikainen

Administrative, technical, or material support: Sariaslan, Haavik, Engeland, Klungsøy, Larsson, Lichtenstein, Martikainen

Supervision: Sariaslan

**Keywords**

Labor epidural analgesia, autism-spectrum disorder, attention-deficit/hyperactivity disorder, family-based designs, causal inference
Condensation: Labor epidural analgesia is not associated with offspring autism spectrum disorder or attention-deficit/hyperactivity disorder after accounting for familial factors.

Short title: Labor epidural analgesia and subsequent risk of offspring autism spectrum disorder and attention-deficit/hyperactivity disorder.
Why was this study conducted?

One previous study has reported an association between labor epidural analgesia and offspring autism-spectrum disorder (ASD), but the causal nature of this association remains unclear. It is possible that elevated depressive and anxiety symptoms in mothers who choose labor epidural analgesia are genetically associated with the ASD risk of their offspring and, as a result, may confound the association between labor epidural analgesia and offspring ASD risk.

Key findings

In this multi-national cohort study of 4,498,462 children and using unexposed siblings as controls to account for shared familial risks (e.g., genetic differences and early-life environments) in addition to measured individual-level confounders, there were no associations between labor epidural analgesia during delivery and offspring ASD or attention-deficit/hyperactivity disorder (ADHD).

What does this add to what is known?

In the largest study of its kind, using total population data derived from three different countries, we did not find support for the hypothesis that exposure to labor epidural analgesia causes an increased risk of either offspring ASD or ADHD. In contrast to previous replication efforts, the current study was able to explicitly account for shared familial risks whilst being sufficiently large to estimate the associations with a high degree of precision. As the decision to use epidural analgesia in labor is unlikely to cause offspring neurodevelopmental disorders, there is no need to revise current clinical guidelines.
Abstract

Background

A recent study has suggested that labor epidural analgesia may be associated with increased rates of offspring autism spectrum disorder (ASD). Subsequent replication attempts have lacked sufficient power to confidently exclude the possibility of a small effect and the causal nature of this association remains unknown.

Objective

To investigate the extent to which exposure to labor epidural analgesia is associated with offspring ASD and attention-deficit/hyperactivity disorder (ADHD) following adjustments for unmeasured familial confounding.

Study design

We identified 4,498,462 singletons and their parents using the Medical Birth Registers in Finland (cohorts born 1987-2005), Norway (1999-2015), and Sweden (1987-2011), linked with population and patient registries. These cohorts were followed from birth until they either had the outcomes of interest, emigrated, died, or reached the end of the follow-up (at mean ages 13.6-16.8 years), whichever occurred first. Cox regression models were used to estimate country-specific associations between labor epidural analgesia recorded at birth and outcomes (e.g., at least one secondary care diagnosis of ASD and ADHD or at least one dispensed prescription of medication used for the treatment of ADHD). The models were adjusted for sex, birth year, birth order, and unmeasured familial confounders via sibling-comparisons. Pooled estimates across all three countries were estimated using inverse variance weighted fixed-effects meta-analysis models.
Results

A total of 4,498,462 individuals (48.7% female) were included, 1,091,846 (24.3%) of which were exposed to labor epidural analgesia. Of these, 1.2% were diagnosed with ASD and 4.0% with ADHD. On the population level, pooled estimates showed that labor epidural analgesia was associated with increased risk of offspring ASD (adjusted hazard ratio, aHR=1.12; 95% CI: 1.10-1.14, absolute risks: 1.20% vs. 1.07%) and ADHD (aHR=1.20; 1.19-1.21; 3.95% vs. 3.32%). However, when comparing full-siblings who were differentially exposed to labor epidural analgesia, the associations were fully attenuated for both conditions, with narrow confidence intervals (aHR_{ASD}=0.98; 0.93-1.03; aHR_{ADHD}=0.99; 0.96-1.02).

Conclusion

In this large cross-national study, we found no support for the hypothesis that exposure to labor epidural analgesia causes either offspring ASD or ADHD.
Introduction

Labor epidural analgesia is commonly used worldwide to provide pain relief to women in labor, as it is effective and considered safe. The most common side effects for mothers are typically temporary and relatively mild (e.g., urinary retention and maternal fever), whilst more serious side effects (e.g., epidural hematoma and deep infections) remain extremely rare. However, few studies have examined long-term outcomes in offspring exposed to labor epidural analgesia. A recent cohort study of nearly 148,000 children in the US reported that labor epidural analgesia may be associated with up to 37% increased risk of offspring autism spectrum disorder (ASD). Criticism of the study, including from several medical societies, have raised concerns about the methodological limitations of the study, the lack of biological plausibility of the proposed association, and the possible clinical implications that an implied causal inference might have.

A key limitation of this and other observational studies is that unmeasured genetic confounders that may simultaneously increase the likelihood of the exposure (i.e., labor epidural analgesia) as well as the outcome (i.e., offspring ASD) have not been adequately accounted for. This is important for two reasons. First, it has been demonstrated that women who elect to give birth using labor epidural analgesia tend to have elevated anxiety and depressive symptoms, which are moderately heritable traits. Second, twin and family-based pedigree studies have consistently found that genetic influences account for approximately 80% of the individual risk differences in ASD, which partly overlap with those explaining individual differences in anxiety and depressive symptoms. It has therefore been recommended that investigations of possible pre- and perinatal risk factors for neurodevelopmental disorders should adopt family-based research designs to account for unmeasured familial confounding (e.g., genetic and early-life environmental risks shared within families).
To our knowledge, there are currently four published replication attempts of the original study,\(^7\) which have used population-based data from Canada\(^{25,26}\) and Denmark\(^{27,28}\) in combination with the genetically informative ‘within-mother’ design, where risks of offspring ASD were compared between maternal siblings who were differentially exposed to labor epidural analgesia.\(^29\) This approach allowed the researchers to account for a portion of the genetic differences shared between siblings.\(^30\) Although these studies have consistently demonstrated that population-wide associations between labor epidural analgesia and offspring ASD (odds/hazard ratio range: 1.05-1.32), were fully attenuated in the adjusted within-mother models, they have lacked sufficient statistical power to confidently exclude the possibility of a small and potentially causal association.

To address these limitations in previous research and to assess the long-term safety of labor epidural analgesia in relation to ASD risk, we used nationwide register data from three Nordic countries (Finland, Norway, and Sweden) to examine the associations between labor epidural analgesia on subsequent risk of offspring ASD across 4.5 million singletons. On the basis of the previous replication studies,\(^{25-28}\) we hypothesized that this association would be fully explained by unmeasured familial confounders. We also investigated attention-deficit/hyperactivity disorder (ADHD) as an outcome as it is a more prevalent neurodevelopmental disorder that shares some of its genetic etiology with autism spectrum disorder.\(^{21,31,32}\) Importantly, to account for unmeasured familial confounders, we combined statistical methods that accounted for measured covariates with a research design that compared outcome rates between biological full siblings who were differentially exposed to labor epidural analgesia. We were able to estimate these associations with greater precision than in previous studies by pooling associations from all three countries and weighting them according to their population sizes using meta-analytic models.
Methods

Study population

We linked several Nordic nationwide population registry data to generate country-specific samples. All residents in Nordic countries are assigned a personal identification number, which is used in respective nationwide registers, and provides accurate linkage. We were granted permission to use pseudonymized data following approvals from the Ethics Board of Statistics Finland (TK-53-1121-18), the Regional Committees for Medical Research Ethics in Norway (2020/75421) and the Regional Ethical Review Board in Stockholm, Sweden (2013/862-31/5). We conducted the data analyses separately on secure servers located in each country. The output, which included the magnitude of the associations and their uncertainties (i.e., standard errors), was then used as input data for a meta-analytical model that estimated the pooled associations across all three countries while accounting for their population size differences. Informed consent is not required for register-based studies in Nordic countries.

We initially identified all singleton children born in Finland 1987-2005 (n=1,125,424), Norway 1999-2015 (n=965,882), and Sweden 1987-2011 (n=2,512,569) using the population-wide Medical Birth Registers in each country, which also provided data on labor epidural analgesia use, offspring gestational age, the mode of delivery, and the maternal age at delivery. The sample thus included a combined total of 4,603,875 children. We then prospectively identified individuals who had ever been diagnosed with ASD and ADHD in the Finnish Care Register for Health Care, which included all inpatient care episodes 1987-2017 and specialist outpatient care visits 1998-2017 according to the ninth and tenth revisions of the International Classification of Diseases (ICD-9 and ICD-10). We similarly identified the same patient groups in the Norwegian Patient Register (inpatient and outpatient care 2008-19, ICD-10), and the Swedish Patient Register (inpatient care: 1987-2013;
outpatient care: 2001-13, ICD-9 and ICD-10). Data on ADHD medications were gathered from the prescribed drug registers in Finland (1995-2018), Norway (2004-19), and Sweden (2005-14).

Migration and mortality dates were retrieved from the population registers in Finland and Norway, and the Migration and Causes of Death registers in Sweden. The average age at the end of follow-up was 15.9 years.

We constructed our analytical sample by excluding individuals who could not be linked to both of their biological parents (n=56,846 [1.2%]), had missing data on gestational age at birth (n=14,846 [0.3%]) and their mode of delivery (n=897 [0.02%]). We further removed those who had either migrated (n=21,383 [0.5%]) or died (n=11441 [0.3%]) before reaching their first birthday in Finland and Sweden, and prior to their fifth birthday in Norway (due to the outcome data being available at a later date). Our analytical sample consequently retained 97.7% of the targeted sample (n=4,498,462). For country-specific sample sizes, see eTable 1.

Exposures and outcomes

Labor epidural analgesia was defined as a binary measure derived from the Medical Birth Registries in each country, where midwives attending birth had recorded the type of, if any, analgesia that the mothers had received in labor. There were no data available on the solution types or dosages used.

We defined individuals who had been diagnosed with ASD (ICD-9: 299, ICD-10: F84) on at least one occasion to have ASD and identified the first observed diagnosis date. Similarly, we defined individuals who had received at least one diagnosis of ADHD (ICD-9: 314, ICD-10 F90) or who at least once dispensed a prescription of medications used nearly exclusively in the treatment of ADHD (Anatomical Therapeutic Chemical codes: N06BA01, N0BA02, N06BA04, N06BA09,
N06BA12) to have ADHD, and identified the first observed diagnosis date or date for first
prescription. Single-episode diagnoses of ASD and ADHD in the national healthcare registers have
been found to have excellent validity (i.e., positive predictive values varying between 88% and 96%)
across Finland,\textsuperscript{39,40} Norway,\textsuperscript{41} and Sweden.\textsuperscript{42,43}

Analytical approach

We quantified the crude population-wide associations between labor epidural analgesia and
subsequent risks for offspring ASD and ADHD, expressed as adjusted hazard ratios (aHRs), using
Cox proportional hazards regression models. The underlying time scale was defined as time from
birth to the first of any of the following events: having the outcome of interest, emigration, death, or
reaching the end of the follow up (Finland: 31 December 2017 for ASD and 31 December 2018 for
ADHD; Norway: 31 December 2019; Sweden: 31 December 2013 for ASD and 31 December 2014
for ADHD). These models were adjusted for sex, birth year (each year as a separate category), and
birth order (categorized into 1, 2, 3 and 4+). To further account for time-stable unmeasured familial
confounding shared between full-siblings (i.e., their shared early-life environments and an average of
half of their co-segregating genes),\textsuperscript{30} we fitted analogous stratified Cox regression models, which
allowed for the baseline hazards to vary across families, thus implying that the risk comparisons
were made within families and between differentially exposed full-siblings.\textsuperscript{30,44} To increase the
precision of the estimates, we subsequently pooled the country-specific estimates using the inverse
variance weighted fixed-effects meta-analytic model, which weighs the estimates from each country
by their relative sample size.\textsuperscript{45}

In complementary sensitivity analyses, we excluded offspring born by cesarean section; those born
prematurely (gestational age <37 weeks); and defined individuals as having ASD or ADHD only if
they had been diagnosed with each condition (or dispensed ADHD medications) at two separate
instances. We additionally examined ADHD as outcome using only the patient data. The sibling-
comparison design assumes that the siblings are generalizable to the full population, and the absence
of any birth order or carry-over effects, namely that the exposure and outcome of a given sibling in a
family do not influence the exposures and outcomes of their co-siblings. To test for these
assumptions, we initially fitted the population-wide models on a subset of all siblings. We then re-
examined the associations in a subset of all first-born cousins in Finland and Sweden who were
differentially exposed to labor epidural analgesia (n=155,299).

Results

We examined a total of 4,498,462 individuals born in Finland (n=1,097,266), Norway (n=929,560)
and Sweden (n=2,471,636) between 1987 and 2015, of which 1,091,846 (24.3%) were exposed to
labor epidural analgesia (Table 1). There was considerable variation in the rates of labor epidural
analgesia across time, ranging from approximately 10% at the baseline of the study to approximately
35%-40% at the end of the follow-ups, with relatively small between-country differences (Figure 1).
Crude absolute risks of the outcomes were marginally elevated among individuals who were exposed
to labor epidural analgesia when compared to unexposed individuals (ASD: 1.20% vs. 1.07%;
ADHD: 3.95% vs. 3.32%; Table 2).

After pooling estimates across all three countries, we found that labor epidural analgesia was
associated with an approximately 12% increased risk of ASD (adjusted hazard ratio, aHR=1.12; 95%
CI: 1.10-1.14) and 20% increased risk of ADHD (aHR=1.20; 1.19-1.21) following adjustments for
sex, birth year and birth order (Figure 2). To further account for shared, unmeasured familial
confounders (e.g., genetic risks and early life environmental factors), we subsequently compared the
hazards of the outcomes between 985,444 full siblings who were differentially exposed to labor
epidural analgesia, of which 24,516 had later developed ASD and 68,991 ADHD (Table 3). We found that those who had been exposed to labor epidural analgesia were no more likely than their unexposed siblings to be diagnosed with either ASD (aHR=0.98; 0.93-1.03) or ADHD (aHR=0.99; 0.96-1.02; Figure 2).

In the complementary sensitivity analyses, we obtained similar estimates as in the main sibling-comparison models when we excluded cesarean deliveries (aHR\textsubscript{ASD}=1.02; 0.96-1.08; aHR\textsubscript{ADHD}=1.01; 0.98-1.05) and those born prematurely (aHR\textsubscript{ASD}=1.00; 0.95-1.06; aHR\textsubscript{ADHD}=1.01; 0.98-1.04). We further found commensurate results when we used stricter definitions by requiring at least two diagnoses or ADHD medication purchases on separate occasions (aHR\textsubscript{ASD}=1.01; 0.95-1.07; aHR\textsubscript{ADHD}=1.00; 0.97-1.03) or by excluding ADHD medication purchases (aHR\textsubscript{ADHD}=0.98; 0.94-1.02). To test for the generalizability of the sibling-comparison estimates, we initially ran the population-wide models in the sibling subsets and found similar results (aHR\textsubscript{ASD}=1.12; 1.09-1.15; aHR\textsubscript{ADHD}=1.20; 1.18-1.22). We subsequently tested for the potential impact of carry-over effects by examining within-extended family associations using first-born cousins who were differentially exposed to labor epidural analgesia. The within-extended family association between labor epidural analgesia and ASD was completely attenuated (aHR=1.02; 0.92-1.12), and the equivalent association with ADHD was attenuated by 35% (aHR=1.13; 1.06-1.20).

Comment

Principal findings

In our cohort study of 4.5 million singleton births in Finland, Norway, and Sweden, including over 985,000 siblings who were differentially exposed to labor epidural analgesia, we did not find support...
for the hypothesis that labor epidural analgesia causes subsequent increased risks of offspring ASD or ADHD.

Results in context
First, in our initial population-wide analyses, we found that labor epidural analgesia was associated with 12 percent increased risk of developing ASD and 20 percent increased risk of developing ADHD. These results are broadly consistent with earlier reports focusing on the population-wide association between labor epidural analgesia and offspring ASD in Denmark, Canada, and the US, although the magnitude of the reported estimates have varied widely across studies (odds/hazard ratio range: 1.05-1.37). Whilst these variations could arise from country and temporal factors, they could be attributed to different methods (e.g., using administrative register data vs. private health insurance data, matching procedures, and statistical model selection).

Second, we found that the associations between labor epidural analgesia and offspring risks of ASD and ADHD were entirely attenuated once we accounted for unmeasured familial confounders (i.e., genetic and early-life environmental influences) shared between biological full siblings who were differentially exposed to labor epidural analgesia. Inconsistent with a causal interpretation, we found that the siblings who were exposed to labor epidural analgesia were no more likely than their unexposed co-siblings to develop either ASD or ADHD. These findings could not be attributed to limited within-family variation in either the exposure or the outcomes, the inclusion of cesarean deliveries and those born pre-term, or stricter outcome definitions.

These findings are in keeping with recent population-based Canadian and Danish studies that used a within-mother design to examine the association between labor epidural analgesia and ASD.
whilst accounting for unmeasured familial confounding. The earlier work had primarily stratified
their models across clusters of mothers, instead of both biological parents, which implies that their
sibling-comparisons included a combination of both full siblings and maternal half-siblings. Such an
approach boosts the statistical power by increasing the number of differentially exposed siblings, but
this comes with the limitation of lower internal validity (i.e., poorer adjustments for unmeasured
genetic confounding as maternal half-siblings share, on average, a quarter of their co-segregating
genes). Although this earlier work did not find that siblings who were exposed to epidural analgesia
during labor were more likely than their unexposed siblings to develop ASD, estimates lacked
statistical power, which resulted in wide confidence intervals. These previous studies could therefore
not exclude the possibility of a moderately sized association, given that upper bounds of the
confidence intervals were consistent with a risk increase ranging between 21%\textsuperscript{25} and 31%.\textsuperscript{26}

Our third main finding is that our pooled sibling-comparison estimate of the same labor epidural
analgesia-ASD association, which was based on a nearly three-fold larger population sample than the
previous studies combined, enabled us to exclude the possibility of non-precise estimation because
the upper bound of its confidence interval was consistent with a negligible maximum risk increase of
2%. Our study therefore adds to the accumulated evidence that does not support a causal
interpretation of the associations between labor epidural analgesia with offspring
neurodevelopmental disorders. Moreover, our findings are consistent with the literature reporting
that a broader set of pre- and perinatal risk markers (e.g., cesarean section deliveries,\textsuperscript{46} labor
induction,\textsuperscript{47,48} maternal infections,\textsuperscript{49} and smoking during pregnancy\textsuperscript{50–52}) are not associated with
offspring neurodevelopmental disorders once unmeasured familial confounders have been
adequately accounted for.
Our findings suggest that current clinical guidelines do not need to revise their recommendation to informing and complying with the requests of pregnant women for labor epidural analgesia, as we have demonstrated that the risks of offspring developing ASD or ADHD as a result of such exposure are, if anything, negligible and not clinically significant.

Our findings further demonstrate that, while sibling comparison designs are effective at accounting for unmeasured familial confounding, they frequently require very large sample sizes to be sufficiently powered to be informative about null results. The latter is because the design is driven by the number of siblings who are differentially exposed to the risk factor of interest and who have different outcomes than their co-siblings. As a result, if either the risk factor or the outcomes are uncommon in a given study, the sibling comparisons will be based on much smaller sample sizes. In the present study, we had three population samples totaling 4.5 million individuals, but our effective sibling sample sizes (i.e., siblings who were differentially exposed to labor epidural analgesia and the neurodevelopmental outcomes) were less than 2% of that ($n_{ASD}=24,516; n_{ADHD}=68,991$). We have shown that it is possible for studies in reproductive epidemiology to harmonize data across different population registers into a common pipeline and pool the associations using meta-analytical techniques to improve on the statistical power of the analyses and thereby increase the precision of the estimates. International collaborations of this nature may therefore be necessary in the future to address etiological research questions with significant clinical implications that require very large sample sizes.
Our study had several important strengths. The combination of nationwide registry data from three Nordic countries, all with universal and accessible high-quality healthcare, enabled us to study 4.5 million individuals whilst keeping selection biases to a minimum. We were able to test for the associations between labor epidural analgesia and externally validated diagnoses of ASD in the offspring. Additionally, we considered offspring ADHD as an outcome due to its clinical significance, common etiology with ASD, and higher prevalence. The inclusion of both conditions contributed to an improvement of the generalizability of our findings. Importantly, we adopted the sibling-comparison design to account for unmeasured familial confounding between biological full-siblings who share their early-life environmental influences and an average of half of their co-segregating genes. The consistency of the risk estimates between the three countries further added to the generalizability of our findings.

Our study had some important limitations. First, we did not have access to outpatient care and prescription drug data across the entire follow-up period for the older cohorts. Additionally, we did not have access to inpatient care data in Norway prior to 2008. We may have consequently overestimated the age at which the conditions were first identified in the older cohorts. However, despite these differences in data availability, the findings remained similar across all three countries, and in the case of ADHD, we also found commensurate results when we excluded medication data. Second, the sibling-comparison design requires very large sample sizes and assumes that the siblings are generalizable to the general population and that no birth order or sibling carry-over effects exist (e.g., exposure of labor epidural analgesia in older siblings affecting the exposure and outcome in their younger co-siblings). We rigorously tested for these assumptions in complementary sensitivity analyses and did not find any evidence that they were violated. Third, while the sibling-comparison design is an effective method for accounting for time-stable unmeasured familial confounders that
are shared between siblings, it requires that non-shared confounders are included as measured covariates in the statistical models.\textsuperscript{30} In the present study, we adjusted for a subset of potential non-shared confounders (i.e., gender, birth year, and birth order), but not all. For instance, as a result of being born in different years, some of the siblings were exposed to different early-life environmental risks compared to their co-siblings, including relative family income poverty\textsuperscript{57,58} and residing in socioeconomically deprived neighborhoods.\textsuperscript{59} Parental separation may have further caused some of the siblings to grow up in different households. However, the inclusion of the latter non-shared confounders would unlikely have altered our findings as the sibling-comparison models yielded null results, indicating that there were no residual associations left to be explained by the adjustment for additional confounders. Fourth, we were unable to assess any potential dose-response effects as we did not have access to data on the duration of labor epidural analgesia exposure. Although this remains an empirical question that could be addressed in future studies, a recent nationwide Danish study\textsuperscript{28} was not able to replicate the dose-response pattern of associations that had been previously reported.\textsuperscript{7}

In relation to generalizability, our estimated prevalence rates of ASD\textsuperscript{60} and ADHD\textsuperscript{61} were similar to rates in other high-income countries. Labor epidural analgesia use increased considerably throughout the follow-up period across the all three countries that we examined with relatively small between country-differences, suggesting that the findings are generalizable across the Nordic countries. Given that our findings were consistent with within-mother associations in Canada,\textsuperscript{25,26} where the rates of labor epidural analgesia use have been consistently high throughout the same time period, suggests that our findings may also be generalizable to other high-income countries.
Conclusions

In the largest study to date examining the associations between labor epidural analgesia and subsequent risks of offspring ASD and ADHD, we found that the associations were entirely attenuated once we accounted for unmeasured familial confounders shared between exposure-discordant full-siblings. In contrast to previous sibling-comparison studies examining these associations, we had sufficient statistical power to confidently exclude the possibility of a larger than negligible association. We conclude that it is unlikely that labor epidural analgesia causes an increased risk of either offspring ASD or ADHD. Pregnant women have therefore no reason to fear that their decision to use epidural analgesia during labor will have any meaningful impact on their offspring’s risk of developing neurodevelopmental disorders, such as ASD or ADHD.


35. Finnish Institute for Health and Welfare. Trends in access to specialised health

556 en/statistics/information-on-statistics/quality-descriptions/trends-in-access-tospecialised-

557 %0Dhealth-care

558 36. Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The Norwegian
559 Patient Registry and the Norwegian Registry for Primary Health Care: Research potential of two


564 HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin


568 40. Joelsson P, Chudal R, Gyllenberg D, et al. Demographic Characteristics and

569 Psychiatric Comorbidity of Children and Adolescents Diagnosed with ADHD in Specialized


572 hos barn i Norge [Diagnosing autism spectrum disorder among children in Norway]. Tidsskr Nor

573 Laegeforen. 2019;139(14).


576 43. Larsson H, Rydén E, Boman M, Längström N, Lichtenstein P, Landén M. Risk of

577 bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity


579 44. Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Diseases in


582 45. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat


585 Neurodevelopmental and Psychiatric Disorders in the Children of a Population-Based Swedish


590 Association Between Labor Induction and Offspring Attention-Deficit Hyperactivity Disorder

592 49. Ginsberg Y, D’Onofrio BM, Rickert ME, et al. Maternal infection requiring

593 hospitalization during pregnancy and attention-deficit hyperactivity disorder in offspring: a


595 50. Skoglund C, Chen Q, D’Onofrio BM, Lichtenstein P, Larsson H. Familial

596 confounding of the association between maternal smoking during pregnancy and ADHD in


599 association between maternal smoking in pregnancy and autism spectrum disorder in offspring.


Table 1. Baseline demographic characteristics

Figure 1. Proportion of births with labor epidural analgesia in Finland, Norway, and Sweden between 1987 and 2015

Table 2. Person-time at risk, number of patients, prevalence rates and incident rates per 1000 person-years for autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD), stratified across individuals exposed to labor epidural analgesia (LEA)

Figure 2. Population-wide and within-family (e.g., sibling-comparison) associations between labor epidural analgesia and later risks of offspring autism-spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in Finland, Norway, Sweden, and their pooled estimates

Notes: All models were adjusted for sex, birth year and birth order. The sibling-comparison models further accounted for unmeasured familial confounders shared between full siblings.

Table 3. The number of siblings who were differentially exposed to labor epidural analgesia, had different outcomes or were both differentially exposed and had different outcomes

Notes: ASD refers to autism-spectrum disorder and ADHD to attention-deficit/hyperactivity disorder.
### eTable 1. Inclusion criteria for the nationwide samples

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Finland</th>
<th>Norway</th>
<th>Sweden</th>
<th>Pooled</th>
<th>Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td>All individuals in the targeted cohorts</td>
<td>1,125,424</td>
<td>965,882</td>
<td>2,512,569</td>
<td>4,603,875</td>
<td>-</td>
</tr>
<tr>
<td>Could be linked to both biological parents</td>
<td>1,112,142</td>
<td>947,128</td>
<td>2,487,759</td>
<td>4,547,029</td>
<td>56,846</td>
</tr>
<tr>
<td>Not missing data on gestational age at birth</td>
<td>1,104,992</td>
<td>941,993</td>
<td>2,485,198</td>
<td>4,532,183</td>
<td>14,846</td>
</tr>
<tr>
<td>Not missing data on cesarean delivery</td>
<td>1,104,095</td>
<td>941,993</td>
<td>2,485,198</td>
<td>4,531,286</td>
<td>897</td>
</tr>
<tr>
<td>Did not migrate before age 1y or 5y*</td>
<td>1,099,580</td>
<td>931,408</td>
<td>2,478,915</td>
<td>4,509,903</td>
<td>21,383</td>
</tr>
<tr>
<td>Did not die before age 1y or 5y*</td>
<td>1,097,266</td>
<td>929,560</td>
<td>2,471,636</td>
<td>4,498,462</td>
<td>11,441</td>
</tr>
</tbody>
</table>

* The prescription drugs register started in 2004 in Norway when the oldest cohort were 5 years of age. The Norwegian National Patient Register had a later start in 2008. We therefore excluded all children who were right-censored before reaching the age of 5 years in the Norwegian sample.
Table 1. Baseline demographic characteristics

<table>
<thead>
<tr>
<th></th>
<th>Finland (n=1,097,266)</th>
<th>Norway (n=929,560)</th>
<th>Sweden (n=2,471,636)</th>
<th>Pooled (n=4,498,462)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unexposed to LEAs</td>
<td>Exposed to LEAs</td>
<td>Unexposed to LEAs</td>
<td>Exposed to LEAs</td>
</tr>
<tr>
<td>Total</td>
<td>829,526 (76.6%)</td>
<td>267,740 (24.4%)</td>
<td>670,362 (72.1%)</td>
<td>259,198 (27.9%)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>407,420 (49.1%)</td>
<td>128,938 (48.2%)</td>
<td>329,084 (49.1%)</td>
<td>123,247</td>
</tr>
<tr>
<td>Male</td>
<td>422,106 (50.9%)</td>
<td>138,802 (51.8%)</td>
<td>341,278 (50.9%)</td>
<td>135,951</td>
</tr>
<tr>
<td>Birth year</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1987-1989</td>
<td>162,751 (19.6%)</td>
<td>14,295 (5.3%)</td>
<td>274,463 (14.4%)</td>
<td>41,631 (7.4%)</td>
</tr>
<tr>
<td>1990-1994</td>
<td>262,623 (31.7%)</td>
<td>48,744 (18.2%)</td>
<td>483,557 (25.4%)</td>
<td>82,529 (14.6%)</td>
</tr>
<tr>
<td>1995-1999</td>
<td>206,376 (24.9%)</td>
<td>77,136 (28.8%)</td>
<td>430,577 (14.4%)</td>
<td>120,099 (21.3%)</td>
</tr>
<tr>
<td>2000-2004</td>
<td>163,917 (19.8%)</td>
<td>202,123 (30.2%)</td>
<td>326,265 (17.1%)</td>
<td>111,164 (19.7%)</td>
</tr>
<tr>
<td>2005-2009</td>
<td>33,859 (4.1%)</td>
<td>21,541 (8.0%)</td>
<td>355,373 (18.6%)</td>
<td>143,164 (25.3%)</td>
</tr>
<tr>
<td>2010-2014</td>
<td>-</td>
<td>189,376 (28.2%)</td>
<td>145,647 (7.6%)</td>
<td>66,321 (11.7%)</td>
</tr>
<tr>
<td>2015</td>
<td>-</td>
<td>34,813 (5.2%)</td>
<td>18,873 (7.3%)</td>
<td>-</td>
</tr>
<tr>
<td>Birth order</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st</td>
<td>329,778 (39.8%)</td>
<td>128,311 (47.9%)</td>
<td>221,631 (33.1%)</td>
<td>161,803 (62.4%)</td>
</tr>
<tr>
<td>2nd</td>
<td>279,418 (33.7%)</td>
<td>92,320 (34.5%)</td>
<td>268,228 (40.0%)</td>
<td>68,201 (26.3%)</td>
</tr>
<tr>
<td>3rd</td>
<td>136,290 (16.4%)</td>
<td>33,027 (12.3%)</td>
<td>127,765 (19.1%)</td>
<td>21,578 (8.3%)</td>
</tr>
<tr>
<td>4th or higher</td>
<td>84,040 (10.1%)</td>
<td>14,082 (5.3%)</td>
<td>52,738 (7.9%)</td>
<td>7616 (2.9%)</td>
</tr>
<tr>
<td>Mother born abroad</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>799,363 (96.4%)</td>
<td>92,320 (95.0%)</td>
<td>535,853 (79.9%)</td>
<td>207,405 (80.0%)</td>
</tr>
<tr>
<td>Yes</td>
<td>30,163 (3.6%)</td>
<td>13,283 (5.0%)</td>
<td>124,724 (18.0%)</td>
<td>48,855 (18.8%)</td>
</tr>
<tr>
<td>Missing</td>
<td>-</td>
<td>9785 (1.5%)</td>
<td>2938 (1.1%)</td>
<td>-</td>
</tr>
<tr>
<td>Maternal age at delivery (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤17</td>
<td>1752 (0.2%)</td>
<td>1362 (0.5%)</td>
<td>1999 (0.3%)</td>
<td>1474 (0.6%)</td>
</tr>
<tr>
<td>18-19</td>
<td>10,365 (1.2%)</td>
<td>7136 (2.7%)</td>
<td>9229 (1.4%)</td>
<td>6348 (2.4%)</td>
</tr>
<tr>
<td>Age Group</td>
<td>Cases</td>
<td>Percentage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-24</td>
<td>117,093 (14.1%)</td>
<td>53,392 (19.9%)</td>
<td>87,975 (13.1%)</td>
<td>45,800 (17.7%)</td>
</tr>
<tr>
<td>25-29</td>
<td>275,765 (33.2%)</td>
<td>94,249 (35.2%)</td>
<td>215,421 (32.1%)</td>
<td>87,862 (33.9%)</td>
</tr>
<tr>
<td>30-34</td>
<td>262,769 (31.7%)</td>
<td>73,961 (27.6%)</td>
<td>229,982 (34.3%)</td>
<td>79,430 (30.6%)</td>
</tr>
<tr>
<td>35-39</td>
<td>128,677 (15.5%)</td>
<td>30,906 (11.5%)</td>
<td>106,436 (15.9%)</td>
<td>32,634 (12.6%)</td>
</tr>
<tr>
<td>40-44</td>
<td>31,201 (3.8%)</td>
<td>6404 (2.4%)</td>
<td>18,556 (2.8%)</td>
<td>5458 (2.1%)</td>
</tr>
<tr>
<td>≥45</td>
<td>1904 (0.2%)</td>
<td>330 (0.1%)</td>
<td>764 (0.1%)</td>
<td>192 (0.1%)</td>
</tr>
<tr>
<td>Country</td>
<td>LEAs</td>
<td>Population size</td>
<td>Person-years at risk</td>
<td>Number of patients</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>-----------------</td>
<td>----------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>ASD</td>
<td>No 829,526 (75.6%)</td>
<td>18,409,039 22.2 (5.7)</td>
<td>8520</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 267,740 (24.4%)</td>
<td>5,017,184 18.7 (5.2)</td>
<td>3743</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>No 829,526 (75.6%)</td>
<td>1,906,4091 23.0 (6.0)</td>
<td>26,744</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 267,740 (24.4%)</td>
<td>5,214,454 19.5 (5.5)</td>
<td>12,344</td>
</tr>
<tr>
<td>Norway</td>
<td>ASD</td>
<td>No 670,362 (72.1%)</td>
<td>8,130,884 12.1 (4.9)</td>
<td>4331</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 259,198 (27.9%)</td>
<td>2,918,292 11.3 (4.9)</td>
<td>1813</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>No 670,362 (72.1%)</td>
<td>8,045,820 12.0 (4.8)</td>
<td>21,802</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 259,198 (27.9%)</td>
<td>2,883,688 11.1 (4.8)</td>
<td>9347</td>
</tr>
<tr>
<td>Sweden</td>
<td>ASD</td>
<td>No 1,906,728 (77.1%)</td>
<td>28,507,860 15.0 (7.5)</td>
<td>23,751</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 564,908 (22.9%)</td>
<td>69,727,41 12.3 (7.0)</td>
<td>7516</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>No 1,906,728 (77.1%)</td>
<td>30,137,810 15.8 (7.5)</td>
<td>64,720</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 564,908 (22.9%)</td>
<td>7,456,083 13.2 (7.0)</td>
<td>21,397</td>
</tr>
<tr>
<td>Pooled</td>
<td>ASD</td>
<td>No 3,406,616 (75.7%)</td>
<td>55,047,783 16.2 (7.5)</td>
<td>36,602</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 1,091,846 (24.3%)</td>
<td>14,908,217 13.6 (6.8)</td>
<td>13,072</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>No 3,406,616 (75.7%)</td>
<td>57,247,721 16.8 (7.7)</td>
<td>113,266</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes 1,091,846 (24.3%)</td>
<td>15,554,223 14.2 (6.9)</td>
<td>43,088</td>
</tr>
</tbody>
</table>
Table 3. The number of siblings who were differentially exposed to labor epidural analgesia, had different outcomes or were both differentially exposed and had different outcomes

<table>
<thead>
<tr>
<th></th>
<th>Number of siblings discordant on:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Labor epidural analgesia</td>
<td>Outcome</td>
<td>Both labor epidural analgesia and outcome</td>
</tr>
<tr>
<td>Finland</td>
<td>ASD</td>
<td>248,132</td>
<td>18,975</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>248,132</td>
<td>54,502</td>
</tr>
<tr>
<td>Norway</td>
<td>ASD</td>
<td>205,053</td>
<td>8080</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>205,053</td>
<td>35,379</td>
</tr>
<tr>
<td>Sweden</td>
<td>ASD</td>
<td>532,259</td>
<td>48,167</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>532,259</td>
<td>116,264</td>
</tr>
<tr>
<td>Pooled</td>
<td>ASD</td>
<td>985,444</td>
<td>75,222</td>
</tr>
<tr>
<td></td>
<td>ADHD</td>
<td>985,444</td>
<td>206,145</td>
</tr>
</tbody>
</table>

Notes: ASD refers to autism-spectrum disorder and ADHD to attention-deficit/hyperactivity disorder.
Adjusted hazard ratio

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Finland</td>
<td>0.98 (95% CI: 0.93 - 1.03)</td>
<td>1.20 (95% CI: 1.15 - 1.25)</td>
<td>1.07 (95% CI: 0.98 - 1.17)</td>
<td>1.18 (95% CI: 1.15 - 1.20)</td>
</tr>
<tr>
<td>Norway</td>
<td>0.97 (95% CI: 0.84 - 1.13)</td>
<td>1.15 (95% CI: 1.07 - 1.14)</td>
<td>0.94 (95% CI: 0.88 - 1.00)</td>
<td>1.22 (95% CI: 1.20 - 1.24)</td>
</tr>
<tr>
<td>Sweden</td>
<td>0.94 (95% CI: 0.88 - 1.00)</td>
<td>1.15 (95% CI: 1.07 - 1.14)</td>
<td>0.94 (95% CI: 0.88 - 1.00)</td>
<td>1.22 (95% CI: 1.20 - 1.24)</td>
</tr>
<tr>
<td>Pooled Sibling-comparisons</td>
<td>0.98 (95% CI: 0.93 - 1.03)</td>
<td>1.20 (95% CI: 1.19 - 1.23)</td>
<td>0.99 (95% CI: 0.96 - 1.17)</td>
<td>1.07 (95% CI: 1.03 - 1.11)</td>
</tr>
<tr>
<td>Pooled Population-wide</td>
<td>1.01 (95% CI: 0.98 - 1.04)</td>
<td>1.12 (95% CI: 1.10 - 1.14)</td>
<td>1.07 (95% CI: 1.02 - 1.13)</td>
<td>1.20 (95% CI: 1.15 - 1.25)</td>
</tr>
</tbody>
</table>